Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Invesco Solar ETF (TAN) Price & Performance

Crispr Therapeutics AGTrade
Invesco Solar ETFTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Invesco Solar ETF — how do they compare? Crispr Therapeutics AG trades at $53.92 (market cap $5.23B), while Invesco Solar ETF trades at $52.5. The key difference: Invesco Solar ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.

CRSPTAN
Market Cap
$5.23B
Sector
HealthSector/Thematic
52-Week High
$76.78$73.95
52-Week Low
$44.34$36.62
Enterprise Value
$3.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.

Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.

Invesco Solar ETF

TAN trades at $53.3, up 2.78% over 24 hours, but technical indicators signal a bearish trend with moving averages showing 11 sell signals versus 2 buys. The ETF faces volatility with a beta of 1.41, as noted by The Motley Fool on August 11, 2026, and recent polysilicon tariffs under the Trump administration have spurred mixed reactions, boosting U.S. solar stocks but raising costs for import-dependent firms, per Reuters on August 7, 2026.

Outlook is cautious due to regulatory uncertainties and high expense ratios, but long-term growth potential exists from AI-driven energy demand. Risks include policy shifts and competition, while institutional sentiment is divided with recent downgrades highlighting valuation concerns.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Invesco Solar ETF

TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.

Read more on TAN